Blue California Publishes Peer-Reviewed Human Clinical Trial on ErgoActive® L-Ergothioneine
The 16-week dose-ranging study evaluated cognitive function, sleep quality, and physiological biomarkers in healthy older adults with self-reported memory concerns.
Rancho Santa Margarita, Calif. (June 30, 2025) — Blue California announces the publication of its clinical trial on ErgoActive® L-ergothioneine in the peer-reviewed journal Nutraceuticals. This randomized, double-blind, placebo-controlled study is the first dose-ranging clinical trial of ergothioneine to assess cognitive function, sleep quality, and physiological biomarkers in healthy older adults.
ErgoActive® is Blue California’s high-purity, nature-identical L-ergothioneine, produced by precision fermentation. Ergothioneine is a naturally occurring antioxidant found in mushrooms and other foods. Researchers are studying its potential role in neuroprotection, mitochondrial function, and healthy aging. The U.S. FDA issued a “no questions” response to Blue California’s GRAS notice (GRN 734).
Clinical trial highlights
The trial enrolled 147 adults aged 55–79 with subjective memory complaints. Participants were randomized to receive 10 mg or 25 mg of ErgoActive® daily, or a placebo, for 16 weeks. Assessments included cognitive performance using CNS Vital Signs, self-reported memory and sleep quality, plasma ergothioneine, leukocyte telomere length, and safety.
- Plasma ergothioneine rose at both doses. The published study reported approximately threefold and sixfold increases at weeks 4 and 16, respectively, with 10 mg daily, and approximately sixfold and sixteenfold increases with 25 mg daily.
- Secondary measures of everyday memory and sleep showed favorable results at 25 mg. Among participants who completed the study per protocol, findings favored 25 mg on subjective prospective memory, the ability to remember a planned action, and ease of getting to sleep.
- Reaction time showed changes that varied across study visits. Both dose groups showed improvements at different points in the trial.
- Composite memory improved from baseline at week 4 in the 25 mg group.
- An exploratory telomere finding warrants further study. Women in the 10 mg group showed a within-group increase in leukocyte telomere length.
- ErgoActive® was well tolerated over 16 weeks. The researchers also reported reductions in the liver enzymes ALT and AST.
Participants reported memory concerns and began the study with a median neurocognitive index score of 105, slightly above average. Their median baseline plasma ergothioneine level was also above a threshold proposed in prior literature. The findings help guide future studies in people with lower baseline ergothioneine levels or lower cognitive performance.
“This publication reflects years of investment in building the scientific foundation for ergothioneine,” said Linda May-Zhang, Ph.D., Vice President of Science & Innovation at Blue California and a co-author of the study. “We focused on healthy individuals with subjective memory complaints, a group often considered at higher risk for cognitive decline, yet still within the window for early intervention. These findings offer clinical evidence that ergothioneine supports neurocognitive and physiological resilience in aging humans and provide a strong foundation for future studies in populations with lower ergothioneine status or greater risk for age-related decline.”
Why this research matters for healthy aging products
Memory and sleep are important considerations for consumers as they age. According to market reports, the global brain health supplements market is projected to reach $23.4 billion by 2030, while sleep solutions are experiencing rapid growth due to rising awareness of their role in longevity and mental performance. Consumers over 50 are particularly motivated to address memory concerns, sleep difficulties, and age-related decline. For brands developing healthy aging products, the ErgoActive® trial provides human data at two daily dose levels and adds to earlier ergothioneine research on cognitive outcomes in older adults with mild cognitive impairment and sleep quality in healthy adults.
A broader commitment to healthy aging research
The trial was conducted as part of Blue California’s ErgoActive® Research Program for Healthy Aging and Longevity. The program supports company-sponsored and investigator-led research through academic partnerships, clinical trials, preclinical studies, and ingredient grants. Blue California thanks CSIRO investigators Dr. Ian Zajac and Dr. Naomi Kakoschke, and independent biostatistician Dr. Barbara Kuhn-Sherlock, for their leadership and contributions to the study.
About ErgoActive® L-ergothioneine
ErgoActive® is Blue California’s branded, high-purity L-ergothioneine ingredient. Its water solubility and neutral taste make it versatile across formats, including tablets, capsules, softgels, gummies, functional foods, and beverages.
Read the full peer-reviewed clinical trial · Explore ErgoActive® L-ergothioneine · Request a sample or discuss your formulation
About Blue California Ingredients
Blue California develops and manufactures ingredients for dietary supplements, functional foods, and beverages. Through ingredient innovation, research partnerships, and production technologies such as precision fermentation, Blue California helps brands develop products for the health and wellness market.